SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

Attention centers on anticipation for the REGAL Phase 3 AML survival readout and SLS009 data at ASH, with heavy speculation that SELLASs larger conference booth could signal a partnership or buyout. Bulls read the booth and the companys silence as positive clues, while skeptics emphasize that neither a deal nor trial success has been confirmed.

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Johnson & Johnson

Speculation that Johnson & Johnson could acquire Sellas Life Sciences (SLS) is a dominant topic, with traders pointing to J&Js oncology ambitions and perceived ties between the companies; no deal is confirmed. The upcoming quarterly report is also drawing attention, alongside debate about JNJs recent trading and valuation.

Sovereign frontier cloud for AI that builds  AI agents are starting to build and operate real software. Agentic organizations are starting to coordinate people, code, data, payments, and governance. Both need a cloud that is sovereign, tamperproof, and always on.  The Internet Computer is that cloud.  Built on more than USD 500 million in R&amp;D, ICP uses advanced blockchain technology and cryptography to run entire software systems end-to-end on the network: websites, apps, services, data, payments, and governance. Code and data are protected by the protocol, replicated across independent nodes, and cannot be silently changed by a cloud provider, backend operator, or attacker.  Cloud engines make this infrastructure sovereign. They let organizations run ICP-powered compute across chosen providers, locations, and jurisdictions while keeping the same tamperproof and always-on guarantees of the network.  This is the real demand ICP serves: sovereign frontier cloud for AI agents and agentic organizations. Agents can build and update software. Organizations can run rules, assets, and governance as verifiable systems. The result is software that stays online, keeps its data, and remains under the control of its owners.  Developers and AI agents can build on the Internet Computer with any AI assistant using the ICP skill library at skills.internetcomputer.org, or by creating apps through conversation with Caffeine AI.  Computation on ICP is paid for by converting $ICP into cycles. $ICP is also used for staking and governance through the Network Nervous System.

Internet Computer

ICP is drawing attention for a sharp price rebound and repeated attempts to break chart resistance, with traders split between expecting a breakout and anticipating another rejection or pullback. Some attribute its moves to broader crypto-market strength, while others point to the projects decentralized-compute and AI-infrastructure narrative, whose adoption remains debated.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLakes BLA submission for sonelokimab in hidradenitis suppurativa is driving discussion as investors await the FDAs decision on whether to accept it for review and the review timeline. Reactions are divided: some see the filing as regulatory progress, while others worry about the drugs competitive prospects, a muted share-price response, and managements plan to commercialize independently rather than pursue a partner or sale.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Teslas recent rally has traders focused on a possible technical breakout, with heavy call buying and short-squeeze speculation ahead of the Roadster event and upcoming earnings. Bulls point to momentum and product enthusiasm, while bears question the valuation and warn the move may be options-driven and vulnerable to a reversal.

Vanguard Index Funds - Vanguard S&P 500 ETF

Vanguard S&P 500 ETF

VOO is drawing attention amid debate over the S&P 500s advance and risks from elevated Treasury yields, oil prices, persistent inflation, and possible Fed rate hikes tied partly to Iran-related energy concerns. The community is split between long-term investors adding to the index and bearish traders warning that high valuations and AI-related concentration could leave stocks vulnerable to a correction.

Neon EVM is the EVM on Solana (currently on devnet), which enables Ethereum-based applications to have access to Solana’s scalability and liquidity without any changes to their codebase. Neon EVM is a smart contract on Solana. Solana is a fast-growing blockchain, Neon EVMs performance has been tested through multiple use cases, and the platform now includes the infrastructure and capabilities to support production level development. Notable Ethereum-based projects starting to build on Neon include Curve and Sobal (Balancer friendly fork). Neon EVM has over 200 projects in its pipeline committed to launching shortly after the launch of mainnet, including blue-chip DeFi protocols, wallets, bridges, fiat on/off ramps, infrastructure, DAO tooling, etc. The focus in the early stages will be providing the infrastructure and technical dependencies needed for a breadth of use cases to expand from EVM chains to Solana. Looking beyond mainnet, the plan is to develop interoperability with Solana smart contracts, full ecosystem compatibility, integration with additional major Ethereum tools and services, EVM support for Saga and an early grants program. Deploying on Neon EVM will onboard new users &amp; increase user activity on Aave by decreasing costs compared to Ethereum and enabling users to take advantage of Solana liquidity and access to the overall ecosystem Neon EVM is an Ethereum Virtual Machine (EVM) built into a Solana smart contract, enabling Ethereum developers to build on Solana and access its native ecosystem without changing their codebases. Neon EVM facilitates the usage of Ethereum tooling by dApp developers to scale and access unaddressed liquidity on Solana. Developers can utilize the vast majority of Ethereum dev tools

Neon EVM

NEON is drawing attention around volatile price swings and intermittent volume spikes, with traders speculating that its thin float could amplify a rebound. Bulls see signs of a bottom or reversal, while bears point to persistent selling and repeated failures to hold gains.

Velo3D, Inc. operates as a technology company, which engages in developing and manufacturing metal laser sintering printing machines for 3D printing. Its products include assure system, flow software, sapphire printer & sapphire XC. The company was founded by Benyamin Buller in June 2014 and is headquartered in Fremont, CA.

Velo3D Inc

Velo3Ds unexplained CFO departure and appointment of an interim consultant are fueling concern about management transparency and possible financial risks, with some traders speculating about dilution or deeper problems. Others view the selloff as an overreaction and say the departure alone does not change the companys growth outlook.

NEAR Protocol is the blockchain for AI. A high-performance, AI-native platform built to power the next generation of decentralized applications and intelligent agents. It provides the infrastructure AI needs to transact, operate, and interact across Web2 and Web3. NEAR combines three core elements: User-Owned AI, which ensures agents act in users’ best interests; Intents and Chain Abstraction, which eliminate blockchain complexity for seamless, goal-driven transactions across chains; and a sharded blockchain architecture that delivers the scalability, speed, and low-cost execution needed for real-world AI and Web3 use. This integrated stack makes NEAR the foundation for building secure, user-owned, AI-native applications at internet scale.

Near

NEAR is drawing attention after launching confidential perpetual trading powered by Hyperliquid, with traders highlighting default position privacy as a differentiator. The move has strengthened bullish chatter around NEARs privacy and AI-agent themes, though some traders view the rally as speculative and anticipate a pullback.

Destiny Tech100, Inc. operates as a non-diversified, closed-end management investment company. The company was founded on November 18, 2020 and is headquartered in Austin, TX.

Destiny Tech100 Inc

DESTINY TECH 100 INC

Anticipation of an Anthropic IPO and a possible S-1 filing is the dominant topic, as traders view DXYZs Anthropic stake as a potential catalyst for a revaluation. Bullish posts point to the funds estimated NAV and discount, while skeptics cite filing uncertainty, limited transparency, and concerns about how its private-company holdings are valued.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


Current Price	$1.32
Prev Close	N/A
Open	N/A
Dividend Yield	N/A
50-Day Moving Average	N/A
Beta	N/A
Avg. Volume	N/A
PE Ratio	N/A

52-Week High	N/A
52-Week Low	N/A
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A

Feed

News

Sentiment

Fundamentals

Info

GBPUSD Fundamentals